Clene's ALS drug shows reduction in disease indicator in mid-stage trial (updated)

Clene

15/06/2023 22:04

(Adds details from the release, background on the disease in
paragraphs 2-4)
       June 15 (Reuters) - Clene  CLNN.O  said on Thursday its
experimental amyotrophic lateral sclerosis (ALS) drug showed
reduction in levels of an indicator believed to be tied with the
disease progression in a mid-stage trial. 
    ALS, also known as Lou Gehrig's disease, is a rare
neurological disease that can break down nerve cells in the
brain and spinal cord that make muscles work, leading to
progressive paralysis and death.
    The drug showed a statistically significant reduction in
levels of the neurofilament protein when compared to a placebo
after 24 weeks of treatment, the company said. 
    Clene said it was exploring the possibility for filing a
marketing application for the drug with the U.S. health
regulator. 
    

 (Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna
Chandra ELuri)
 ((Raghav.Mahobe@thomsonreuters.com;))